Compound ID | 2705
Synonym(s): RG6006
Class: Antimicrobial peptide
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against carbapenem-resistant Acinetobacter baumannii; targets the LptB2FGC complex in the Gram-negative inner membrane blocking lipopolysaccharide transport |
| Propensity to select resistant mutants: | Yes, at 10^-7 to 10^-9 mutation frequency |
| Description: | Synthetic compound from the Tranzyme Pharma compound library (RO7075573) which was further modified to produce this second-generation antibiotic; >5-log reduction in neutropenic mouse thigh Acinetobacter baumannii infection model; a macrocyclic peptide |
| Institute where first reported: | Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland |
| Year first mentioned: | 2024 |
| Highest developmental phase: | Phase 1 (NCT05614895) |
| Development status: | Active (as of 2024) |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/148636827 |
| Guide to Pharmacology: | zosurabalpin |
| Citations: |
|
| Patent: | US2019321440A1 |